- Eton licensed patent rights from Baylor College of Medicine for ET-900 (mecasermin) in infantile spasms.
- An IND has been submitted for an investigator-sponsored Phase 2 trial, with dosing expected in Q1 2027.
- Broadens commercial pipeline into pediatric neurology utilizing an already marketed active ingredient.
?? Positive AI Sentiment (+3.0 / 10)